{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:49:27Z","timestamp":1787597367190,"version":"build-2736575974"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82125034"],"award-info":[{"award-number":["82125034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330115"],"award-info":[{"award-number":["82330115"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1302100"],"award-info":[{"award-number":["2021YFA1302100"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1300200"],"award-info":[{"award-number":["2021YFA1300200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.bmc.2024.117967","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T02:17:28Z","timestamp":1730081848000},"page":"117967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The application of PROTACs in immune-inflammation diseases"],"prefix":"10.1016","volume":"115","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2024.117967_b0005","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.bmc.2024.117967_b0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s12016-008-8074-1","article-title":"Rituximab: beyond simple b cell depletion","volume":"34","author":"Kessel","year":"2008","journal-title":"Clinic Rev Allerg Immunol."},{"key":"10.1016\/j.bmc.2024.117967_b0015","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2024.117967_b0020","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2024.117967_b0025","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2004.030783","article-title":"Psoriatic arthritis therapy: NSAIDs and traditional DMARDs","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2024.117967_b0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00472","article-title":"The emerging jamboree of transformative therapies for autoimmune diseases","volume":"11","author":"Carballido","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2024.117967_b0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in nsclc","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2024.117967_b0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmc.2024.117967_b0045","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2024.117967_b0050","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"PROTACs: chimeric molecules that target proteins to the skp1\u2013cullin\u2013f box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.bmc.2024.117967_b0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2024.117967_b0060","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1039\/D2CS00220E","article-title":"Chemistries of bifunctional PROTAC degraders","volume":"51","author":"Cao","year":"2022","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.bmc.2024.117967_b0065","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables\u2014the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci Bull"},{"key":"10.1016\/j.bmc.2024.117967_b0070","doi-asserted-by":"crossref","first-page":"8798","DOI":"10.1021\/acs.jmedchem.2c00728","article-title":"Homobivalent, trivalent, and covalent PROTACs: Emerging strategies for protein degradation","volume":"65","author":"Yan","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0075","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1039\/D4MD00142G","article-title":"Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review","volume":"15","author":"Galla","year":"2024","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0080","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88\u2013IRAK4\u2013IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2024.117967_b0085","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.molcel.2014.08.006","article-title":"IRAK4 dimerization and trans -autophosphorylation are induced by myddosome assembly","volume":"55","author":"Ferrao","year":"2014","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2024.117967_b0090","doi-asserted-by":"crossref","first-page":"15195","DOI":"10.1074\/jbc.RA118.003314","article-title":"Interleukin-1 receptor\u2013associated kinase 4 (IRAK4) plays a dual role in myddosome formation and toll-like receptor signaling","volume":"293","author":"De Nardo","year":"2018","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0095","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1038\/s41591-023-02635-7","article-title":"IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial","volume":"29","author":"Ackerman","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.bmc.2024.117967_b0100","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acsmedchemlett.9b00219","article-title":"Targeting IRAK4 for degradation with PROTACs","volume":"10","author":"Nunes","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117967_b0105","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.chembiol.2020.08.010","article-title":"Assessing IRAK4 functions in ABC DLBCL by IRAK4 kinase inhibition and protein degradation","volume":"27","author":"Zhang","year":"2020","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2024.117967_b0110","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1021\/acsmedchemlett.0c00474","article-title":"Design, synthesis, and biological evaluation of IRAK4-targeting protacs","volume":"12","author":"Chen","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117967_b0115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00213-019-05379-w","article-title":"The protective effect of geniposide on diabetic cognitive impairment through BTK\/TLR4\/NF-\u03baB pathway","volume":"237","author":"Liu","year":"2019","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.bmc.2024.117967_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102842","article-title":"Targeting ITK signaling for T cell-mediated diseases","author":"Weeks","year":"2021","journal-title":"iScience."},{"key":"10.1016\/j.bmc.2024.117967_b0125","doi-asserted-by":"crossref","first-page":"4979","DOI":"10.1021\/acs.jmedchem.2c02078","article-title":"Discovery of potent and highly selective interleukin-2-inducible T-cell kinase degraders with in vivo activity","volume":"66","author":"Zhou","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chembiol.2023.03.007","article-title":"ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas","volume":"30","author":"Jiang","year":"2023","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.bmc.2024.117967_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115664","article-title":"Discovery of ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-\u03baB activation","volume":"259","author":"Huang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0140","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41421-024-00711-x","article-title":"PROTAC for bruton\u2019s tyrosine kinase degradation alleviates inflammation in autoimmune diseases","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov."},{"key":"10.1016\/j.bmc.2024.117967_b0145","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2024.117967_b0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41467-018-08027-7","article-title":"Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase","volume":"10","author":"Smith","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2024.117967_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112451","article-title":"Optimal linker length for small molecule PROTACs that selectively target p38\u03b1 and p38\u03b2 for degradation","volume":"201","author":"Donoghue","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3390\/cancers15030611","article-title":"Synthesis and biological activity of a VHL-based PROTAC specific for p38\u03b1","volume":"15","author":"Cubillos-Rojas","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2024.117967_b0165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.bmc.2024.117967_b0170","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.bmc.2024.117967_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115326","article-title":"Hi-jak-ing the ubiquitin system: the design and physicochemical optimisation of JAK PROTACs","volume":"28","author":"Shah","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0180","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1182\/blood.2020006846","article-title":"Degradation of janus kinases in crlf2-rearranged acute lymphoblastic leukemia","volume":"138","author":"Chang","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2024.117967_b0185","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acsmedchemlett.1c00650","article-title":"Development of potent and selective janus kinase 2\/3 directing PG\u2013PROTACs","volume":"13","author":"Alcock","year":"2022","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117967_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.129083","article-title":"Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor","volume":"79","author":"Kato","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117967_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110128","article-title":"RIPK2 as a promising druggable target for autoimmune diseases","volume":"118","author":"Zhao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2024.117967_b0200","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.bmc.2024.117967_b0205","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s42003-020-0868-6","article-title":"Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2","volume":"3","author":"Mares","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.bmc.2024.117967_b0210","doi-asserted-by":"crossref","first-page":"12978","DOI":"10.1021\/acs.jmedchem.1c01118","article-title":"Optimization of a series of RIPK2 PROTACs","volume":"64","author":"Miah","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0215","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.molcel.2023.03.029","article-title":"The mechanism of STING autoinhibition and activation","volume":"83","author":"Liu","year":"2023","journal-title":"Mol Cell"},{"key":"10.1016\/j.bmc.2024.117967_b0220","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1021\/acs.jmedchem.1c01948","article-title":"Novel CRBN-recruiting proteolysis-targeting chimeras as degraders of stimulator of interferon genes with in vivo anti-inflammatory efficacy","volume":"65","author":"Liu","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0225","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00018-023-04796-7","article-title":"Development of VHL-recruiting STING PROTACs that suppress innate immunity","volume":"80","author":"Zhu","year":"2023","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.bmc.2024.117967_b0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.prostaglandins.2011.05.001","article-title":"Inhibition of hematopoietic prostaglandin D synthase improves allergic nasal blockage in guinea pigs","volume":"95","author":"Nabe","year":"2011","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.bmc.2024.117967_b0235","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3390\/cells8060619","article-title":"Therapeutic potential of hematopoietic prostaglandin D2 synthase in allergic inflammation","volume":"8","author":"Rittchen","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.bmc.2024.117967_b0240","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/acsmedchemlett.0c00605","article-title":"Development of a hematopoietic prostaglandin D synthase-degradation inducer","volume":"12","author":"Yokoo","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2024.117967_b0245","doi-asserted-by":"crossref","first-page":"15868","DOI":"10.1021\/acs.jmedchem.1c01206","article-title":"Discovery of a highly potent and selective degrader targeting hematopoietic prostaglandin D synthase via in silico design","volume":"64","author":"Yokoo","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0250","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejmech.2018.03.066","article-title":"Phthalimide conjugations for the degradation of oncogenic PI3K","volume":"151","author":"Li","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0255","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/acs.jmedchem.6b01872","article-title":"Chemically induced degradation of sirtuin 2 (sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (sirreals)","volume":"61","author":"Schiedel","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0260","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2024.117967_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117033","article-title":"A comprehensive review of bet-targeting protacs for cancer therapy","volume":"73","author":"Zhou","year":"2022","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2024.117967_b0270","first-page":"409","article-title":"PROTACs targeting epigenetic proteins","volume":"2","author":"Zhang","year":"2023","journal-title":"Acta Mater Med."}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962400381X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096808962400381X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T09:57:43Z","timestamp":1738144663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096808962400381X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":54,"alternative-id":["S096808962400381X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117967","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The application of PROTACs in immune-inflammation diseases","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2024.117967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117967"}}